Literature DB >> 5721980

Plasma levels and urinary excretion of hexamethylmelamine following oral administration to human subjects with cancer.

G T Bryan, J F Worzalla, A L Gorske, G Ramirez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5721980     DOI： 10.1002/cpt196896777

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 2.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

Authors:  E Garattini; T Colombo; M G Donelli; P Catalani; M Bianchi; M D'Incalci; C Pantarotto
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.

Authors:  M D'Incalci; E Erba; G Balconi; L Morasca; S Garattini
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

5.  Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour.

Authors:  A E Bateman; M J Peckham; G G Steel
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.